company background image
ENTX

Entera BioNasdaqCM:ENTX Stock Report

Market Cap

US$122.8m

7D

-5.5%

1Y

288.2%

Updated

22 Oct, 2021

Data

Company Financials +
ENTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ENTX Overview

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs.

Price History & Performance

Summary of all time highs, changes and price drops for Entera Bio
Historical stock prices
Current Share PriceUS$4.27
52 Week HighUS$1.01
52 Week LowUS$10.16
Beta1.66
1 Month Change-11.59%
3 Month Change-19.59%
1 Year Change288.18%
3 Year Change-23.89%
5 Year Changen/a
Change since IPO-32.01%

Recent News & Updates

Oct 06
We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ENTXUS BiotechsUS Market
7D-5.5%0.5%1.7%
1Y288.2%16.1%30.3%

Return vs Industry: ENTX exceeded the US Biotechs industry which returned 17.1% over the past year.

Return vs Market: ENTX exceeded the US Market which returned 31.1% over the past year.

Price Volatility

Is ENTX's price volatile compared to industry and market?
ENTX volatility
ENTX Beta1.66
Industry Beta0.98
Market Beta1

Stable Share Price: ENTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ENTX's weekly volatility has decreased from 28% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200919Spiros Jamashttps://www.enterabio.com

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures.

Entera Bio Fundamentals Summary

How do Entera Bio's earnings and revenue compare to its market cap?
ENTX fundamental statistics
Market CapUS$122.80m
Earnings (TTM)-US$18.52m
Revenue (TTM)US$537.00k

228.7x

P/S Ratio

-6.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENTX income statement (TTM)
RevenueUS$537.00k
Cost of RevenueUS$257.00k
Gross ProfitUS$280.00k
ExpensesUS$18.80m
Earnings-US$18.52m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.64
Gross Margin52.14%
Net Profit Margin-3,448.23%
Debt/Equity Ratio0%

How did ENTX perform over the long term?

See historical performance and comparison

Valuation

Is Entera Bio undervalued compared to its fair value and its price relative to the market?

4.85x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ENTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ENTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ENTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ENTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ENTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ENTX is overvalued based on its PB Ratio (4.9x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Entera Bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

58.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ENTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ENTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ENTX's revenue (87.7% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: ENTX's revenue (87.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ENTX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Entera Bio performed over the past 5 years?

-20.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ENTX is currently unprofitable.

Growing Profit Margin: ENTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ENTX is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare ENTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: ENTX has a negative Return on Equity (-73.15%), as it is currently unprofitable.


Financial Health

How is Entera Bio's financial position?


Financial Position Analysis

Short Term Liabilities: ENTX's short term assets ($27.9M) exceed its short term liabilities ($3.3M).

Long Term Liabilities: ENTX's short term assets ($27.9M) exceed its long term liabilities ($275.0K).


Debt to Equity History and Analysis

Debt Level: ENTX is debt free.

Reducing Debt: ENTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ENTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ENTX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 21.2% each year.


Dividend

What is Entera Bio current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ENTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ENTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Spiros Jamas (60 yo)

0.75

Tenure

Dr. Spiros Jamas, Sc D., serves as the Chief Executive Officer & Director of Entera Bio Ltd since January 4, 2021. He served as the Chief Executive Officer and President at Tempero Pharmaceuticals, Inc. fr...


Leadership Team

Experienced Management: ENTX's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: ENTX's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 57.7%.


Top Shareholders

Company Information

Entera Bio Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Entera Bio Ltd.
  • Ticker: ENTX
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$122.796m
  • Shares outstanding: 28.76m
  • Website: https://www.enterabio.com

Number of Employees


Location

  • Entera Bio Ltd.
  • Kiryat Hadassah Minrav Building
  • Fifth Floor
  • Jerusalem
  • 9122002
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/22 23:06
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.